Ramucirumab for advanced hepatocellular carcinoma in the current real world: a Japanese single-arm study post-REACH-2 (The R-evolution study)
Investigational New Drugs · 2024-08 · 42 (4) · 394-404
DOI: 10.1007/s10637-024-01441-3 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Investigational New Drugs, online erschienen am 06.06.2024. Verfasst von Kazufumi Kobayashi und 33 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan. Hauptthemen laut MEDLINE: Ramucirumab, Carcinoma, Hepatocellular, Liver Neoplasms, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
This study aimed to complement the results of the REACH-2 study by prospectively evaluating the safety and efficacy of ramucirumab in advanced hepatocellular carcinoma (HCC) in a real-world setting. This was an open-label, nonrandomized, multicenter, prospective study conducted at 13 institutions in Japan (jRCTs031190236). The study included Child–Pugh Class A patients with advanced HCC who had received pretreatment with atezolizumab plus bevacizumab (Atez/Bev) or lenvatinib. Ramucirumab was introduced as a second-line treatment after Atez/Bev or lenvatinib and as a third-line treatment after Atez/Bev and lenvatinib. Between May 2020 and July 2022, we enrolled 19 patients, including 17 who received ramucirumab. Additionally, seven patients received lenvatinib, another seven patients received Atez/Bev, and three patients received Atez/Bev followed by lenvatinib as prior treatment. The primary endpoint was a 6-month progression-free survival (PFS) rate, which was 14.3%. The median PFS and overall survival were 3.7 and 12.0 months, respectively. The most common grade ≥ 3 adverse events (AEs) were hypertension (23.5%), proteinuria (17.6%), and neutropenia (11.8%). The discontinuation rate due to AEs was 29.4%. Six patients progressed from Child–Pugh A to B after treatment with ramucirumab. Thirteen patients were eligible for post-ramucirumab treatment, including systemic therapy. Despite the limited number of patients, the efficacy of ramucirumab was comparable to that observed in the REACH-2 study when used after lenvatinib and Atez/Bev. However, the incidence of AEs was higher than that in the REACH-2 study.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
- Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan. ogasawaras@chiba-u.jp.
- Department of Gastroenterology, Asahi General Hospital, Asahi, Japan.
- Division of Gastroenterology, Department of Internal Medicine, Nippon Medical School Chiba Hokusoh Hospital, Inzai, Japan.
- Department of Gastroenterology, Chiba Cancer Center, Chiba, Japan.
- Department of Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Zitieren
APA
Kobayashi, K., Ogasawara, S., Itobayashi, E., Okubo, T., Itokawa, N., Nakamura, K., Moriguchi, M., Watanabe, S., Ikeda, M., Kuroda, H., Kawaoka, T., Hiraoka, A., Yasui, Y., Kuzuya, T., Sato, R., Kanzaki, H., Koroki, K., Inoue, M., Nakamura, M., …, & Kato, N. (2024). Ramucirumab for advanced hepatocellular carcinoma in the current real world: a Japanese single-arm study post-REACH-2 (The R-evolution study). Investigational New Drugs, 42(4), 394-404. https://doi.org/10.1007/s10637-024-01441-3
Vancouver
Kobayashi K, Ogasawara S, Itobayashi E, Okubo T, Itokawa N, Nakamura K, et al. Ramucirumab for advanced hepatocellular carcinoma in the current real world: a Japanese single-arm study post-REACH-2 (The R-evolution study). Investigational New Drugs. 2024;42(4):394-404. doi:10.1007/s10637-024-01441-3
BibTeX
@article{Kobayashi2024,
author = {Kobayashi, Kazufumi and Ogasawara, Sadahisa and Itobayashi, Ei and Okubo, Tomomi and Itokawa, Norio and Nakamura, Kazuyoshi and Moriguchi, Michihisa and Watanabe, Shunji and Ikeda, Masafumi and Kuroda, Hidekatsu and Kawaoka, Tomokazu and Hiraoka, Atsushi and Yasui, Yutaka and Kuzuya, Teiji and Sato, Rui and Kanzaki, Hiroaki and Koroki, Keisuke and Inoue, Masanori and Nakamura, Masato and Kiyono, Soichiro and Kanogawa, Naoya and Kondo, Takayuki and Nakamoto, Shingo and Ozawa, Yoshihito and Tsuchiya, Kaoru and Atsukawa, Masanori and Aikata, Hiroshi and Aramaki, Takeshi and Oka, Shiro and Morimoto, Naoki and Kurosaki, Masayuki and Itoh, Yoshito and Izumi, Namiki and Kato, Naoya},
title = {Ramucirumab for advanced hepatocellular carcinoma in the current real world: a Japanese single-arm study post-REACH-2 (The R-evolution study)},
journal = {Investigational New Drugs},
year = {2024},
volume = {42},
number = {4},
pages = {394--404},
doi = {10.1007/s10637-024-01441-3}
}
EUVIMED